Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)

Thomas O. Bergmeijer, Jean‐Luc Reny, Ruth E. Pakyz, Li Gong, Joshua P. Lewis, Eun Young Kim, Dániel Aradi, Israel Fernández‐Cadenas, Richard B. Horenstein, Ming Ta Michael Lee, Ryan Whaley, Joan Montaner, Gian Franco Gensini, John H. Cleator, Kiyuk Chang, Lene Holmvang, Willibald Hochholzer, D M Roden, Stefan Winter, Russ B. Altman, Dimitrios Alexopoulos, Ho-Sook Kim, Jean‐Pierre Déry, Meinrad Gawaz, Kevin P. Bliden, Marco Valgimigli, Rossella Marcucci, Gianluca Campo, Elke Schaeffeler, Nadia Dridi, Ming‐Shien Wen, Jae Gook Shin, Tabassome Simon, Pierre Fontana, Betti Giusti, Tobias Geisler, Michiaki Kubo, Dietmar Trenk, Jolanta M. Siller‐Matula, Jurriën M. ten Berg, Paul A. Gurbel, Jean‐Sébastien Hulot, Braxton D. Mitchell, Matthias Schwab, Marylyn D. Ritchie, Teri E. Klein, Alan R. ShuldinerAmerican 2017 · DOI

TL;DR

This paper introduces the International Clopidogrel Pharmacogenomics Consortium (ICPC), a large-scale collaborative effort to identify genetic factors influencing how well clopidogrel, a common antiplatelet drug, works. By combining genetic data with platelet function and clinical outcome data from nearly 9,000 patients, the ICPC aims to uncover new genetic determinants of clopidogrel response, paving the way for more personalized antiplatelet therapy.

What Problem Does This Paper Address?

Clopidogrel is a widely prescribed drug to prevent blood clots in patients with conditions like acute coronary syndrome or after undergoing percutaneous coronary intervention (PCI). However, its effectiveness varies significantly between individuals, leading to a higher risk of either thrombotic events (if the drug isn't working well enough) or bleeding complications (if it's too potent). While the CYP2C19 gene is known to play a role in this variability, heritability estimates suggest that other genetic factors are also at play, and these remain largely unidentified. The challenge is to systematically identify these additional genetic contributors to optimize clopidogrel therapy and improve patient outcomes.

Methods

The ICPC employed a multi-pronged approach:

  • Collaborative Data Aggregation: The study invited lead investigators from clopidogrel-related clinical studies to share anonymized patient data. This included DNA samples, platelet function test results, patient characteristics, and cardiovascular outcomes.
  • Standardized Phenotyping: While different studies used various platelet function assays (VASP, LTA, VerifyNow P2Y12), the ICPC developed a priority system to standardize these measurements into a Z-score, allowing for meta-analysis across diverse datasets.
  • Genotyping: A two-pronged genetic analysis was planned:
  • Candidate Gene Approach: Focusing on genes with prior evidence linking them to clopidogrel response.
  • Genome-Wide Association Study (GWAS): Utilizing the Illumina Omni Express with Exome (OEE) chip to scan the entire genome for novel genetic associations without pre-selection.
  • Data Management and Analysis: A centralized data coordinating center at Stanford University (PharmGKB) managed data curation, and genetic analyses were coordinated at the University of Maryland. Robust quality control pipelines, including those from the eMERGE network, were used for genotype data cleaning and imputation.

Datasets

The primary dataset for the ICPC comprises data from 8,829 patients treated with clopidogrel. This includes:

  • Platelet function data: Available for 6,270 patients.
  • Clinical outcome data: Available for 5,819 patients.
  • DNA samples: Available for 5,119 patients, with genotyping planned.

The paper also references data from www.clinicaltrials.gov for identifying eligible studies. A proof-of-principle analysis validated the database by confirming the known association between CYP2C19 *2 and platelet reactivity in a subset of 5,328 Caucasian patients.

Key Insights and Ideas

  • The Power of Collaboration: The ICPC demonstrates the immense value of large-scale international collaboration in pharmacogenomics, pooling resources and data to achieve statistical power unattainable by individual studies.
  • Beyond CYP2C19: While CYP2C19 is a known player, the heritability estimates strongly suggest that other genetic factors significantly contribute to clopidogrel response variability, highlighting the need for comprehensive genomic approaches.
  • Standardization is Crucial: The effort to standardize diverse platelet function assays into a common metric (Z-scores) is a critical methodological innovation that enables robust cross-study comparisons.
  • A Resource for Future Research: The ICPC has created a valuable genomic discovery resource that will serve as a platform for testing new hypotheses and replicating findings from other research groups.

Key Results

  • The ICPC successfully recruited 17 study sites from 13 countries, contributing data from 8,829 patients.
  • A proof-of-principle analysis confirmed a strong and consistent association between the CYP2C19 *2 polymorphism and platelet reactivity (p-value = 5.1×10⁻⁴⁰).
  • In a subset of 5,328 Caucasian patients, CYP2C19 *2 was independently associated with higher on-treatment platelet reactivity (Beta = 0.37; p-value = 5.1×10⁻⁴⁰).
  • The study aims to identify novel genetic loci that explain the substantial remaining variability in clopidogrel response, which is estimated to have a heritability as high as 70%.

Limitations and Future Work

  • Limitations:
    • The paper acknowledges that while CYP2C19 *2 is a major determinant, it only accounts for approximately 4–12% of the observed inter-individual variation in antiplatelet effect.
  • The study design relies on data from previously conducted studies, which may have inherent variations in protocols or data collection.
  • While the ICPC aims to standardize platelet function tests, the use of multiple assays inherently introduces some level of variability.
  • Future Work:
    • The ICPC will proceed with candidate gene and genome-wide association studies to identify novel genetic determinants of clopidogrel pharmacodynamics and clinical response.
  • The consortium aims to serve as a well-powered resource for testing new hypotheses and welcomes proposals for ancillary projects from qualified investigators.
  • The ICPC will also function as a replication cohort for genetic variants identified by other research groups.
  • The ultimate goal is to leverage this genetic information to develop personalized antiplatelet strategies, improving patient care and potentially reducing costs associated with adverse events.

Summary updated

BibTeX
@inproceedings{bergmeijer2017genome,
  author = {Thomas O. Bergmeijer and Jean‐Luc Reny and Ruth E. Pakyz and Li Gong and Joshua P. Lewis and Eun Young Kim and Dániel Aradi and Israel Fernández‐Cadenas and Richard B. Horenstein and Ming Ta Michael Lee and Ryan Whaley and Joan Montaner and Gian Franco Gensini and John H. Cleator and Kiyuk Chang and Lene Holmvang and Willibald Hochholzer and D M Roden and Stefan Winter and Russ B. Altman and Dimitrios Alexopoulos and Ho-Sook Kim and Jean‐Pierre Déry and Meinrad Gawaz and Kevin P. Bliden and Marco Valgimigli and Rossella Marcucci and Gianluca Campo and Elke Schaeffeler and Nadia Dridi and Ming‐Shien Wen and Jae Gook Shin and Tabassome Simon and Pierre Fontana and Betti Giusti and Tobias Geisler and Michiaki Kubo and Dietmar Trenk and Jolanta M. Siller‐Matula and Jurriën M. ten Berg and Paul A. Gurbel and Jean‐Sébastien Hulot and Braxton D. Mitchell and Matthias Schwab and Marylyn D. Ritchie and Teri E. Klein and Alan R. Shuldiner},
  title = {{Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)}},
  booktitle = {American},
  year = {2017},
  doi = {10.1016/j.ahj.2017.12.010},
}
Figure